Considerations for improved performance of competition association assays analysed with the Motulsky–Mahan's “kinetics of competitive binding” model

Abstract

Background and Purpose: Target engagement dynamics can influence drugs' pharmacological effects. Kinetic parameters for drug:target interactions are often quantified by evaluating competition association experiments-measuring simultaneous protein binding of labelled tracers and unlabelled test compounds over time-with Motulsky-Mahan's "kinetics of competitive binding" model. Despite recent technical improvements, the current assay formats impose practical limitations to this approach. This study aims at the characterisation, understanding and prevention of these experimental constraints, and associated analytical challenges. Experimental Approach: Monte Carlo simulations were used to run virtual kinetic and equilibrium tracer binding and competition experiments in both normal and perturbed assay conditions. Data were fitted to standard equations derived from the mass action law (including Motulsky-Mahan's) and to extended versions aiming to cope with frequently observed deviations of the canonical traces. Results were compared to assess the precision and accuracy of these models and identify experimental factors influencing their performance. Key Results: Key factors influencing the precision and accuracy of the Motulsky-Mahan model are the interplay between compound dissociation rates, measurement time and interval frequency, tracer concentration and binding kinetics and the relative abundance of equilibrium complexes in vehicle controls. Experimental results produced recommendations for better design of tracer characterisation experiments and new strategies to deal with systematic signal decay.Conclusions and Implications: Our data advances our comprehension of the Motulsky-Mahan kinetics of competitive binding models and provides experimental design recommendations, data analysis tools, and general guidelines for its practical application to in vitro pharmacology and drug screening. ---This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Single-molecule Dynamic In-Solution Inhibition Assay: A Method for Full Kinetic Profiling of Drug Candidate Binding to GPCRs in Native Membranes

“…In a corresponding ensemble-based ISA experiment, the temporal evolution of the net change in TDC occupancy ( ) at > inh is given by 26,38 ( and where TDC is the concentration of suspended TDC. Although Eq.…”

“…radioactive labelling or fluorescence resonance energy transfer 26 . Nonetheless, as repeatedly shown, [27][28][29] the kinetic window in terms of on and off values that can be quantified is strictly restricted by the kinetic profile of the TDC in relation to that of the screening compound. Further, if the TDC is instead immobilized on a surface with the competition measured using SPR, BLI, or OWG, only d can be determined and TDC has to have a very slow dissociation rate in such studies 30,31 .…”

The Problems of Applying Classical Pharmacology Analysis to Modern In Vitro Drug Discovery Assays: Slow Binding Kinetics and High Target Concentration

“…7,52,53 It should noted that while measuring the rate constants is an effective way to measure affinity, kinetic binding assays require significant resources for assay development and data analysis. [59][60][61]…”

A rebinding-assay for measuring extreme kinetics using label-free biosensors

“…A biosensor-based approach has recently been reported 11 , addressing this limitation but specific system customizations are required to enable routine application. Probe-based kinetic competition assays 12 may be implemented using surface plasmon resonance (SPR)-based biosensors 13 , or other equivalent flow-injection-based biosensors such as grating coupled interfereometry 14 . However, the estimation of transient kinetics and extremely rapid association processes (i.e.…”